CAMBRIDGE, Mass. – Jan. 17, 2019 – eGenesis, a biotechnology company revolutionizing the field of transplantation with its multiplexed gene editing platform, today announced the appointment of Paul Sekhri as president and chief executive officer, effective immediately.
eGenesis is a life sciences company focused on leveraging gene editing technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
300 Technology Square, Suite 301
Cambridge, MA 02139